Cancer Res Treat.  2018 Oct;50(4):1458-1461. 10.4143/crt.2017.529.

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report

• Song HN
• Kang MG
• Park JR
• Hwang JY
• Kang JH
• Lee WS
• Lee GW

• KMID: 2424816
• DOI: http://doi.org/10.4143/crt.2017.529

Abstract

Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.

Keyword

Sarcoma; Immunotherapy; Pembrolizumab

MeSH Terms

Drug Therapy
Humans
Immunotherapy
Radiotherapy
Sarcoma

Figure

• 

  Fig. 1. (A) Electrocardiogram showing ST segment elevation in leads V2 to V5. (B) Coronary angiography image showing complete occlusion at the mid-left anterior descending artery (arrow).

• 

  Fig. 2. Histopathologic findings of aspirated specimens: anaplasia and pleomorphism of the nucleus compatible with high-grade metastatic sarcoma (H&E staining, ×40).

• 

  Fig. 3. (A) Baseline chest computed tomography (CT) image shows multiple metastatic lung mass with tumor invasion to the left atrium from the pulmonary vein. (B) Follow-up CT image shows a partial response after two cycles of pembrolizumab and a slight decrease in the size of the multiple masses in both the lung and left atrium. (C) Follow-up CT image shows a partial response after four cycles of pembrolizumab and a marked decrease in the size of the multiple masses in both the lung and left atrium.

Reference

References

1. Lazaros GA, Matsakas EP, Madas JS, Toli DI, Nikas DJ, Kershaw MA, et al. Primary myxofibrosarcoma of the left atrium: case report and review of the literature. Angiology. 2008; 59:632–5.

2. McMillan RR, Sima CS, Moraco NH, Rusch VW, Huang J. Recurrence patterns after resection of soft tissue sarcomas of the chest wall. Ann Thorac Surg. 2013; 96:1223–8.

3. Kikuta K, Kubota D, Yoshida A, Suzuki Y, Morioka H, Toyama Y, et al. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol. 2013; 43:1093–104.

4. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 17:976–83.

5. Zschabitz S, Lasitschka F, Hadaschik B, Hofheinz RD, Jentsch-Ullrich K, Gruner M, et al. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. Eur J Cancer. 2017; 76:1–7.

6. Rexer H, Steiner T, Grunwald V. First-line therapy in advanced renal cell carcinoma: a randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO. Urologe A. 2017; 56:509–11.

7. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376:1015–26.

8. Fletcher CD, Unni KK, Mertens F. World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press;2002. p. 102–3.

9. Nascimento AF, Bertoni F, Fletcher CD. Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol. 2007; 31:99–105.

10. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515:568–71.

11. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016; 22:5487–96.

12. Zhu Z, Jin Z, Zhang M, Tang Y, Yang G, Yuan X, et al. Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis. Oncotarget. 2017; 8:59570–80.

13. Kosemehmetoglu K, Ozogul E, Babaoglu B, Tezel GG, Gedikoglu G. Programmed death ligand 1 (PD-L1) expression in malignant mesenchymal tumors. Turk Patoloji Derg. 2017; 1:192–7.

14. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18:1493–501.

15. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins JN, Milhem MM, Tap WD, et al. A multi-center phase II study of nivolumab +/– ipilimumab for patients with metastatic sarcoma (Alliance A091401). J Clin Oncol. 2017; 35 Suppl:Abstr 11007.